# Evidence-Based Clinical Review

**Peptide & Pharmaceutical Protocol Evaluation**

---

## Methodological Framework

### Evidence Hierarchy

| Level | Description | Example |
|-------|-------------|---------|
| **I** | High-quality RCTs, meta-analyses | FDA-approved drugs with Phase III trials |
| **II** | Smaller RCTs, well-designed cohort studies | ITP lifespan studies, TRIIM trial |
| **III** | Case-control studies, observational data | Epidemiological associations |
| **IV** | Case series, mechanistic studies, animal data | Most peptide research |
| **V** | Expert opinion, theoretical rationale | Synergy hypotheses |

### Critical Appraisal Criteria

1. **Human data** — Evidence in humans vs animal/in vitro only
2. **Endpoint quality** — Hard outcomes (mortality) vs surrogate markers
3. **Regulatory status** — FDA/EMA approval and indication
4. **Safety profile** — Known adverse effects, long-term data
5. **Mechanistic plausibility** — Scientific support for proposed mechanism

---

## Pharmaceuticals

| Compound | Protocol(s) | Level | Regulatory | Key Evidence |
|----------|-------------|-------|------------|--------------|
| Rapamycin | A, P | II | Off-label | ITP: 9-14% lifespan extension; VIBRANT: 20% slower ovarian aging |
| Metformin | T, A, P | I | FDA | Decades of data; TAME trial ongoing; diabetics outlive controls |
| Repatha (Evolocumab) | P | I | FDA | FOURIER: 15% CV event reduction, 59% LDL reduction |
| Tirzepatide | T, A, P | I | FDA | SURPASS/SURMOUNT trials; superior to GLP-1 alone |
| HGH (rhGH) | P | I-II | FDA | TRIIM: 2.5-year epigenetic age reversal; oncogenic concern Level III* |
| Testosterone | T, A, P | I | FDA | Extensive safety/efficacy data; foundation compound |
| Estradiol | A | I | FDA | Decades of HRT research; bone, CV, cognition |
| Progesterone | A | I | FDA | HRT component; sleep, mood, uterine protection |
| Cabergoline | A | I | FDA | Prolactin control; cardiac monitoring if >12 months |
| 17-alpha Estradiol | P (M) | II | Research | ITP: 19% male lifespan extension; non-feminising |
| DHEA | P | II | Supplement | TRIIM component; adrenal/immune support |
| Low-Dose Aspirin | P | I | OTC | 2.1M patient study: 13% CRC reduction |
| LDN | P | III | Off-label | Immune modulation; NK cell enhancement; opioid contraindication |
| Procyanidin C1 | T, A, P | III | Supplement | Senolytic; pulsed dosing (3 days/month) |
| Teriparatide | A (optional) | I | FDA | Bone anabolic; max 2 years; severe osteoporosis |

*T = Titan, A = Athena, P = Prometheus*

**\*Level III oncogenic concern:** Epidemiological studies associate elevated IGF-1 with increased cancer incidence. Association, not causation — no RCTs demonstrate HGH causes cancer.

---

## Peptides

| Compound | Protocol(s) | Level | Regulatory | Key Evidence | Oncogenic Concern |
|----------|-------------|-------|------------|--------------|-------------------|
| Tesamorelin | T, A, P | II | FDA | Phase III for lipodystrophy; controlled GH release | Epidemiological (III)* |
| Thymosin Alpha-1 | P | II | 35+ countries | Sepsis meta-analysis: 9% mortality reduction | Low |
| PT-141 | A | I | FDA | Approved 2019 for female HSDD | Negligible |
| Epithalon | T, A, P | III | Research | Khavinson: telomerase activation in human cells | Low (may be protective) |
| NAD+ | A, P | II-III | Research | NMN/NR trials: insulin sensitivity, muscle function | Low |
| SS-31 | T, A, P | III | Investigational | Phase II: cardiac improvement in Barth syndrome, HF | Low |
| MOTS-c | T, A, P | III | Research | Human trials: exercise-mimetic, glucose handling | Low |
| Thymalin | T, P | III | Foreign-approved | Soviet-era research; immune restoration | Low |
| Selank | A, P | III | Foreign-approved | Russian approval; anxiolytic without sedation | Negligible |
| Semax | T, A | III | Foreign-approved | Russian approval; BDNF, cognitive enhancement | Negligible |
| DSIP | T, A | IV | Research | Sleep architecture studies; no large RCTs | Low |
| KPV | P | IV | Research | Alpha-MSH fragment; anti-inflammatory mechanism | Low |
| Kisspeptin-10 | A | III | Research | Reproductive endocrine studies; GnRH regulation | Low |
| GHK-Cu | T, A | III | Research | Wound healing trials; 28% collagen increase | Theoretical (V)** |
| Follistatin-344 | T | IV | Research | Myostatin inhibition validated; human data sparse | Theoretical (V)** |
| Dihexa | T | IV | Research | Single laboratory; HGF/c-Met mechanism | Theoretical (V)*** |
| BPC-157 | T, A | IV | Research | Extensive animal data; zero human trials | Theoretical (V)** |
| TB-500 | T | IV | Research | Wound healing animal data; no human trials | Theoretical (V)** |

### Oncogenic Concern Classification

Oncogenic concern is graded by evidence level, not assumed risk magnitude:

| Grade | Basis | Compounds |
|-------|-------|-----------|
| **Epidemiological (III)*** | Observational studies associating elevated IGF-1 with cancer incidence (prostate, breast, colorectal). Association, not causation. | HGH, Tesamorelin (GH axis) |
| **Theoretical (V)**** | Angiogenic properties in animal wound healing studies. Concern: angiogenesis could theoretically feed occult tumours. No human cancer data. | BPC-157, TB-500, GHK-Cu (systemic), Follistatin-344 |
| **Theoretical (V)***** | HGF/c-Met is a known oncogenic pathway in cancer biology. No human data on Dihexa specifically. Pathway-based inference only. | Dihexa |

**Key distinction:** GH/IGF-1 concerns have Level III epidemiological support. All other oncogenic concerns are Level V mechanistic inferences with no human evidence of cancer causation.

---

## Supplements

| Compound | Protocol(s) | Level | Key Evidence |
|----------|-------------|-------|--------------|
| Ca-AKG | T, A, P | III | Rejuvant trial: 8-year biological age reversal |
| Creatine | T, A, P | I | Extensive RCTs: ATP, muscle, cognitive benefits |
| Omega-3 | T, A, P | I | CV outcomes, brain health, anti-inflammatory |
| Vitamin D3 | T, A, P | I | Bone, immune, muscle; target 50-80 ng/mL |
| Vitamin K2 (MK-7) | A, P | II | Calcium direction to bones; CV protection |
| Magnesium Glycinate | T, A, P | I | Sleep, CV, muscle relaxation |
| CoQ10 (Ubiquinol) | T, A, P | II | Mitochondrial ETC; heart failure data |
| TMG | T, A, P | II | Methyl donor; critical with Metformin (B12 depletion) |
| Glycine | T, A, P | II | Glutathione precursor; collagen; sleep |
| NAC | T, A, P | I | Glutathione precursor; mucolytic; antioxidant |
| Zinc | T, P | I | Immune function; thymulin cofactor (TRIIM) |
| Taurine | P | II | CV protection; ITP interest compound |
| Spermidine | P | II | Autophagy induction; observational longevity data |
| Fisetin | P | III | Mayo Clinic senolytic pilot; pulsed dosing |
| L-Theanine | P | II | Calm focus; GABA modulation |
| Lithium Orotate | A, P | III | Neuroprotection; mood stability at low doses |
| Alpha-GPC | T | II | Acetylcholine precursor; cognitive support |
| Collagen Peptides | A | II | Skin elasticity; joint support trials |
| Boron | A | II | Bone density; extends D3 half-life 20% |
| Myo-Inositol | A | I | PCOS trials; insulin sensitivity; egg quality |
| DIM | A | III | Estrogen metabolism; 2-OH:16-OH ratio |
| Biotin | A | II | Hair, nails; well-established |

---

## Protocol Risk Profiles

### Oncogenic Concern by Protocol

**Prometheus**
- GH-pathway compounds: HGH, Tesamorelin — epidemiological concern (Level III)
- Excludes angiogenic peptides (BPC-157, TB-500, GHK-Cu systemic)
- Oncoprotective stack included: Metformin, Rapamycin, Aspirin, LDN, Thymosin Alpha-1

**Athena**
- GH-pathway: Tesamorelin — epidemiological concern (Level III)
- BPC-157 — theoretical concern (Level V, angiogenic mechanism)
- Rapamycin provides partial counterbalance

**Titan**
- GH-pathway: Tesamorelin — epidemiological concern (Level III)
- BPC-157, TB-500, GHK-Cu, Follistatin-344 — theoretical concern (Level V, angiogenic/proliferative)
- Dihexa — theoretical concern (Level V, HGF/c-Met pathway)
- No oncoprotective pharmaceutical stack

### Critical Drug Interactions

| Compound | Interaction | Action |
|----------|-------------|--------|
| LDN | ANY opioids | Absolute contraindication — precipitates withdrawal |
| Rapamycin | CYP3A4 inhibitors | Grapefruit, azole antifungals, clarithromycin increase levels |
| Rapamycin | Surgery | Hold 1-2 weeks pre-procedure (wound healing) |
| Aspirin | Surgery | Hold 7 days pre-procedure |
| Metformin | IV contrast | Hold 48h before/after |

---

## Evidence Summary

### Strongest Evidence (Level I-II)
- Rapamycin, Metformin, Testosterone, Estradiol, Repatha, Tirzepatide
- Creatine, Omega-3, Vitamin D3, Magnesium, NAC
- Tesamorelin, PT-141, Thymosin Alpha-1
- TRIIM combination (HGH + DHEA + Metformin)

### Moderate Evidence (Level II-III)
- 17-alpha Estradiol (ITP), Epithalon, NAD+, Ca-AKG
- SS-31, MOTS-c, Selank, Semax
- Fisetin, Procyanidin C1 (senolytics)
- CoQ10, Taurine, Spermidine, TMG

### Limited Evidence (Level IV)
- BPC-157, TB-500, Dihexa, Follistatin-344
- DSIP, KPV, GHK-Cu (systemic)

---

## Key References

- Fahy GM et al. (2019). Aging Cell. [TRIIM trial — epigenetic age reversal]
- FOURIER Trial (2017). NEJM. [Evolocumab CV outcomes]
- Harrison DE et al. (2009). Nature. [ITP Rapamycin]
- Strong R et al. (2016). Aging Cell. [ITP 17α-estradiol]
- Khavinson VK et al. (2003). Bull Exp Biol Med. [Epithalon telomerase]
- Demidenko ON et al. (2023). Aging. [Ca-AKG biological age]

---

*Document Version: 2.2 | December 2024*
